《Veeva：2025生物制药行业客户参与未来展望白皮书（英文版）（21页）.pdf》由会员分享，可在线阅读，更多相关《Veeva：2025生物制药行业客户参与未来展望白皮书（英文版）（21页）.pdf（21页珍藏版）》请在三个皮匠报告上搜索。

1、WHITE PAPERThe Future of Customer Engagement in BiopharmaThe past three decades have seen a rapid rise in specialty drugs.Thirty years ago,roughly 10 were on the U.S.market;today,there are 671 FDA-approved biologics.1 In 2023,the European Medicines Agency recommended 77 drugs for marketing authoriza

2、tion,including 39 new active substances and 17 orphan drugs supporting treatments for rare diseases.2 The growth gives new hope to healthcare professionals(HCPs)and their patients who lack viable treatment options.But progress doesnt come without challenges.As complex and expensive treatment options

3、 proliferate,so does the demand to demonstrate and communicate your products value.Todays engagement strategies often fall short of getting relevant messages and offerings to market to influence better patient outcomes.Functional silos and traditional ways of working only make this harder,adding ine

4、fficiency and cost as well as reducing impact.Its time to re-examine your approach.This paper explores future-proof customer engagement strategies and guides on how to strengthen relationships with HCPs,healthcare organizations(HCOs),payers,and patients to secure patient access and improve outcomes.

5、1 FDA at a Glance Fact Sheet,U.S.Food&Drug Administration,April 20232 Human medicines:highlights of 2023,European Medicines Agency,January 2024An enhanced customer experience,built on mutual value exchange and enabled by connected engagementThe Future of Customer Engagement in Biopharma 2As you stri

6、ve to prioritize your customers needs,it may feel as though the ground below is shifting.Historically,having feet on the street mattered greatly in winning share of voice and relaying key messages to HCPs.When the majority of drugs were blockbuster or population-based,the customers and decision-make